128 related articles for article (PubMed ID: 25965834)
1. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Khanna A; Rane JK; Kivinummi KK; Urbanucci A; Helenius MA; Tolonen TT; Saramäki OR; Latonen L; Manni V; Pimanda JE; Maitland NJ; Westermarck J; Visakorpi T
Oncotarget; 2015 Aug; 6(23):19661-70. PubMed ID: 25965834
[TBL] [Abstract][Full Text] [Related]
2. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
[TBL] [Abstract][Full Text] [Related]
3. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer.
Fontana F; Limonta P
Cells; 2021 May; 10(5):. PubMed ID: 34067217
[TBL] [Abstract][Full Text] [Related]
6.
Kato T; Kawakami K; Mizutani K; Ando T; Sakai Y; Sakurai K; Toyota S; Ehara H; Ito H; Ito M
Cancer Genomics Proteomics; 2023; 20(5):456-468. PubMed ID: 37643783
[TBL] [Abstract][Full Text] [Related]
7. A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells.
Imberg-Kazdan K; Ha S; Greenfield A; Poultney CS; Bonneau R; Logan SK; Garabedian MJ
Genome Res; 2013 Apr; 23(4):581-91. PubMed ID: 23403032
[TBL] [Abstract][Full Text] [Related]
8. Tanshinone analog inhibits castration-resistant prostate cancer cell growth by inhibiting glycolysis in an AR-dependent manner.
Yu J; Li S; Cheng S; Ahmad M; Chen C; Wan X; Wei S; Pan W; Luo H
J Biol Chem; 2024 Apr; 300(4):107139. PubMed ID: 38447792
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells.
Muniyan S; Chou YW; Ingersoll MA; Devine A; Morris M; Odero-Marah VA; Khan SA; Chaney WG; Bu XR; Lin MF
Cancer Lett; 2014 Oct; 353(1):59-67. PubMed ID: 25050738
[TBL] [Abstract][Full Text] [Related]
10. Dynein axonemal heavy chain 8 promotes androgen receptor activity and associates with prostate cancer progression.
Wang Y; Ledet RJ; Imberg-Kazdan K; Logan SK; Garabedian MJ
Oncotarget; 2016 Aug; 7(31):49268-49280. PubMed ID: 27363033
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of FAM84B during prostate cancer progression.
Wong N; Gu Y; Kapoor A; Lin X; Ojo D; Wei F; Yan J; de Melo J; Major P; Wood G; Aziz T; Cutz JC; Bonert M; Patterson AJ; Tang D
Oncotarget; 2017 Mar; 8(12):19218-19235. PubMed ID: 28186973
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.
De P; Carlson J; Leyland-Jones B; Dey N
Oncotarget; 2014 Jul; 5(13):4581-602. PubMed ID: 25015035
[TBL] [Abstract][Full Text] [Related]
13. [Mechanism study on the effect of androgen antagonism in prostate cancer].
Song X; Song Q; Wang R; Zuo QJ; Zhang ZY
Zhonghua Nan Ke Xue; 2023 May; 29(5):402-408. PubMed ID: 38602755
[TBL] [Abstract][Full Text] [Related]
14. Autocrine amphiregulin signaling sustains castration-resistant Ly6d
Xin L
Trends Cell Biol; 2023 Aug; 33(8):619-620. PubMed ID: 37331831
[TBL] [Abstract][Full Text] [Related]
15. Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.
Cristóbal I; Rojo F; Madoz-Gúrpide J; García-Foncillas J
Mol Cell Biol; 2016 Jun; 36(12):1734-9. PubMed ID: 27090640
[TBL] [Abstract][Full Text] [Related]
16. Oncoprotein CIP2A promotes the disassembly of primary cilia and inhibits glycolytic metabolism.
Jeong AL; Ka HI; Han S; Lee S; Lee EW; Soh SJ; Joo HJ; Sumiyasuren B; Park JY; Lim JS; Park JH; Lee MS; Yang Y
EMBO Rep; 2018 May; 19(5):. PubMed ID: 29491003
[TBL] [Abstract][Full Text] [Related]
17. Emerging proteins involved in castration‑resistant prostate cancer via the AR‑dependent and AR‑independent pathways (Review).
Feng K; Liu C; Wang W; Kong P; Tao Z; Liu W
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37732538
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression.
Angappulige DH; Mahajan NP; Mahajan K
Trends Cancer; 2024 Apr; 10(4):369-381. PubMed ID: 38341319
[TBL] [Abstract][Full Text] [Related]
19. Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting.
Pienta KJ; Walia G; Simons JW; Soule HR
Prostate; 2014 Feb; 74(3):314-20. PubMed ID: 24249419
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of orthotopic castration-resistant prostate cancer growth and metastasis in mice by JC VLPs carrying a suicide gene driven by the PSA promoter.
Chou CC; Tseng CE; Lin YS; Wang M; Chen PL; Chang D; Shen CH; Fang CY
Cancer Gene Ther; 2024 Feb; 31(2):250-258. PubMed ID: 38072969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
